PL3658141T3 - Leczenie stanów patologicznych przez bezpośrednie i pośrednie celowanie w oddziaływanie sirpalfa - cd47 - Google Patents
Leczenie stanów patologicznych przez bezpośrednie i pośrednie celowanie w oddziaływanie sirpalfa - cd47Info
- Publication number
- PL3658141T3 PL3658141T3 PL18770099.2T PL18770099T PL3658141T3 PL 3658141 T3 PL3658141 T3 PL 3658141T3 PL 18770099 T PL18770099 T PL 18770099T PL 3658141 T3 PL3658141 T3 PL 3658141T3
- Authority
- PL
- Poland
- Prior art keywords
- sirpalpha
- interaction
- direct
- pathological conditions
- treating pathological
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2019333 | 2017-07-24 | ||
NL2020938 | 2018-05-15 | ||
PCT/NL2018/050515 WO2019022600A1 (en) | 2017-07-24 | 2018-07-24 | TREATMENT OF PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA INTERACTION - CD47 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL3658141T3 true PL3658141T3 (pl) | 2023-06-12 |
Family
ID=63592774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL18770099.2T PL3658141T3 (pl) | 2017-07-24 | 2018-07-24 | Leczenie stanów patologicznych przez bezpośrednie i pośrednie celowanie w oddziaływanie sirpalfa - cd47 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20190365717A1 (pl) |
EP (3) | EP3747438A1 (pl) |
AU (2) | AU2018308191B2 (pl) |
CA (1) | CA3070828A1 (pl) |
DK (1) | DK3658141T3 (pl) |
ES (1) | ES2938445T3 (pl) |
FI (1) | FI3658141T3 (pl) |
PL (1) | PL3658141T3 (pl) |
WO (1) | WO2019022600A1 (pl) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018107058A1 (en) | 2016-12-09 | 2018-06-14 | Alector Llc | Anti-sirp-alpha antibodies and methods of use thereof |
FI3658141T3 (fi) | 2017-07-24 | 2023-03-02 | Patologisten tilojen hoitaminen suoralla tai epäsuoralla siralfa-cd47-vuorovaikutukseen kohdentamisella | |
KR20200059249A (ko) | 2017-09-21 | 2020-05-28 | 유엠씨 우트레크트 홀딩 비.브이. | 신경아세포종의 치료를 위한 항-gd2 항체 |
US10973878B2 (en) * | 2017-10-26 | 2021-04-13 | Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. | Recombinant fusion protein containing an anti-PD-L1 antibody |
AU2019272885A1 (en) | 2018-05-25 | 2020-11-26 | Alector Llc | Anti-SIRPA antibodies and methods of use thereof |
US11591390B2 (en) | 2018-09-27 | 2023-02-28 | Celgene Corporation | SIRP-α binding proteins and methods of use thereof |
JP2022506761A (ja) * | 2018-10-29 | 2022-01-17 | ティガティーエックス,インコーポレーテッド | IgA抗体構築物を含む組成物および方法 |
EP3947441A1 (en) | 2019-03-27 | 2022-02-09 | UMC Utrecht Holding B.V. | Engineered iga antibodies and methods of use |
CN111647623B (zh) * | 2020-07-14 | 2022-03-18 | 江苏集萃药康生物科技股份有限公司 | 一种sirpa人源化动物模型的构建方法及其应用 |
CN118019737A (zh) | 2021-06-24 | 2024-05-10 | 英矽智能科技知识产权有限公司 | 用于治疗疾病的β-内酰胺衍生物 |
AU2022203580A1 (en) * | 2021-09-17 | 2023-04-06 | Academia Sinica | Methods of Increasing Cell Phagocytosis |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1620082B9 (en) | 2003-05-05 | 2010-08-25 | Probiodrug AG | Medical use of inhibitors of glutaminyl and glutamate cyclases for treating alzheimer's disease and down syndrome |
ZA200508439B (en) | 2003-05-05 | 2007-03-28 | Probiodrug Ag | Medical use of inhibitors of glutaminyl and glutamate cyclases |
JP5707014B2 (ja) | 2003-10-15 | 2015-04-22 | プロビオドルグ エージー | グルタミニル、及びグルタミン酸シクラーゼのエフェクターの使用 |
EP1713780B1 (en) | 2004-02-05 | 2012-01-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
EA016584B1 (ru) * | 2006-09-21 | 2012-06-29 | Пробиодруг Аг | Новые гены, родственные гену глутаминилциклазы |
US8889709B2 (en) | 2006-09-21 | 2014-11-18 | Probiodrug Ag | Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions |
CN101668525A (zh) * | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
DK2160380T3 (da) | 2007-04-18 | 2014-06-30 | Probiodrug Ag | Cyano-guanidin derivater som glutaminyl cyclase inhibitorer |
SG178953A1 (en) * | 2009-09-11 | 2012-04-27 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
PT2812443T (pt) | 2012-02-06 | 2019-09-05 | Inhibrx Inc | Anticorpos cd47 e métodos de utilização dos mesmos |
SI3721888T1 (sl) | 2013-02-05 | 2023-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Tarčne terapije proti CD47 za zdravljenje infekcijske bolezni |
CN105263927B (zh) | 2013-03-15 | 2019-03-15 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂 |
ES2765483T3 (es) * | 2013-09-18 | 2020-06-09 | Univ Leland Stanford Junior | Modulación de las vías de eferocitosis para el tratamiento de una enfermedad aterosclerótica |
JOP20200096A1 (ar) * | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
US9993494B2 (en) | 2014-02-07 | 2018-06-12 | Effector Therapeutics, Inc. | Compositions and methods for treating fibrotic disease |
EP3116544A4 (en) * | 2014-03-11 | 2017-08-23 | The Board of Trustees of the Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
JP2018535692A (ja) | 2015-09-21 | 2018-12-06 | エラスムス ユニバーシティ メディカル センターErasmus University Medical Center | 抗cd47抗体及び使用方法 |
US20180318260A1 (en) * | 2015-11-04 | 2018-11-08 | The Scripps Research Institute | Compositions and methods for treating cystic fibrosis |
FI3658141T3 (fi) | 2017-07-24 | 2023-03-02 | Patologisten tilojen hoitaminen suoralla tai epäsuoralla siralfa-cd47-vuorovaikutukseen kohdentamisella |
-
2018
- 2018-07-24 FI FIEP18770099.2T patent/FI3658141T3/fi active
- 2018-07-24 DK DK18770099.2T patent/DK3658141T3/da active
- 2018-07-24 EP EP20183635.0A patent/EP3747438A1/en not_active Withdrawn
- 2018-07-24 ES ES18770099T patent/ES2938445T3/es active Active
- 2018-07-24 EP EP20183625.1A patent/EP3747437A1/en active Pending
- 2018-07-24 WO PCT/NL2018/050515 patent/WO2019022600A1/en unknown
- 2018-07-24 EP EP18770099.2A patent/EP3658141B1/en active Active
- 2018-07-24 CA CA3070828A patent/CA3070828A1/en active Pending
- 2018-07-24 AU AU2018308191A patent/AU2018308191B2/en active Active
- 2018-07-24 PL PL18770099.2T patent/PL3658141T3/pl unknown
-
2019
- 2019-04-26 US US16/396,083 patent/US20190365717A1/en active Pending
-
2021
- 2021-04-23 US US17/238,909 patent/US20220087981A1/en active Pending
-
2024
- 2024-03-07 AU AU2024201512A patent/AU2024201512A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220087981A1 (en) | 2022-03-24 |
FI3658141T3 (fi) | 2023-03-02 |
DK3658141T3 (da) | 2023-02-06 |
AU2018308191B2 (en) | 2023-12-21 |
WO2019022600A1 (en) | 2019-01-31 |
EP3658141B1 (en) | 2022-11-16 |
EP3747437A1 (en) | 2020-12-09 |
ES2938445T3 (es) | 2023-04-11 |
CA3070828A1 (en) | 2019-01-31 |
US20190365717A1 (en) | 2019-12-05 |
AU2024201512A1 (en) | 2024-03-28 |
AU2018308191A1 (en) | 2020-02-27 |
EP3747438A1 (en) | 2020-12-09 |
EP3658141A1 (en) | 2020-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3658141T3 (pl) | Leczenie stanów patologicznych przez bezpośrednie i pośrednie celowanie w oddziaływanie sirpalfa - cd47 | |
IL269026A (en) | Tumor treatment methods | |
IL275663A (en) | Cancer treatment methods | |
ZA202006746B (en) | Methods of treatment | |
HK1251409A1 (zh) | 治療癌症的方法 | |
IL285151B1 (en) | Methods for the treatment of fgf21-related disorders | |
ZA201804227B (en) | Methods of treating cancer | |
IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
IL269082A (en) | Methods for treating lysosomal disorders | |
ZA201907401B (en) | Treatment of adipocytes | |
IL272092A (en) | Methods for treating changes in behavior | |
IL271934A (en) | Methods for treating tumor metastases | |
IL270781A (en) | Treatment of depressive disorders | |
SG11202005163PA (en) | Methods of treating cancer | |
SG11201605745VA (en) | Targeting clptm1l for treatment and prevention of cancer | |
IL267613A (en) | Pancreatic cancer treatment | |
HUE053089T2 (hu) | Migrén kezelése acetil-leucinnal | |
GB201713760D0 (en) | Treatment of epilepsy | |
IL274748A (en) | Improved cancer treatment | |
IL269123A (en) | Methods of treating cancer | |
IL272379A (en) | Methods for treating cancer using SETDS inhibition | |
SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
GB201713763D0 (en) | Treatment of epilepsy | |
GB201713762D0 (en) | Treatment of epilepsy | |
GB201704287D0 (en) | Treatment of cancer |